Smart Nanoparticle Platform Targets Injured Kidneys and Neutralizes Damaging Oxidative Stress

Acute kidney injury (AKI) affects over 13 million people annually and carries mortality rates exceeding 50% in severe cases. Its pathogenesis involves a destructive cycle of oxidative stress, inflammation, and tubular cell apoptosis, yet no targeted pharmacological therapies exist. This study addresses that gap with a sophisticated, multi-functional nanoplatform called CeAst@MK.

The core nanoparticle, CeAst, is formed by coordinating cerium ions (Ce³⁺) with astragalin (Ast), a natural flavonoid from Eucommia ulmoides identified via network pharmacology as a high-priority AKI therapeutic candidate. Molecular docking confirmed strong binding of Ast to AKT1 (−9.0 kcal/mol). The cerium component provides catalytic antioxidant activity by mimicking superoxide dismutase (SOD) and catalase (CAT) through reversible Ce³⁺/Ce⁴⁺ redox cycling, while Ast contributes direct ROS scavenging and anti-inflammatory properties. The nanoparticles are then coated with macrophage cell membranes (MCM) from RAW264.7 cells to confer immune evasion and inflammatory-site homing, and further functionalized with a kidney-targeting peptide (KTP) that recognizes KIM-1, a biomarker upregulated on injured tubular cells.

Characterization confirmed successful assembly: CeAst measured ~56 nm by TEM, growing to ~89 nm after membrane coating. XPS analysis revealed a Ce³⁺/Ce⁴⁺ ratio of 0.86, supporting dual enzyme-mimetic activity. FT-IR and UV-vis spectroscopy confirmed Ce³⁺–Ast coordination. Critically, in vitro release studies demonstrated pH-responsive Ast release, with markedly accelerated release at pH 5.5–6.5, matching the acidic microenvironment of injured renal tubules in AKI.

In vivo testing in both LPS-induced septic AKI and ischemia-reperfusion injury (IRI) mouse models showed that CeAst@MK significantly improved serum creatinine and BUN levels (markers of kidney function), reduced histological damage, suppressed pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and promoted M1-to-M2 macrophage polarization. Mechanistically, the platform modulated the PI3K/Akt and NF-κB signaling pathways, achieving coordinated antioxidative and anti-inflammatory effects. Biodistribution data confirmed preferential renal accumulation compared to non-targeted controls.

This work represents a compelling convergence of natural product pharmacology, cerium nanomedicine, biomimetic membrane engineering, and active targeting. The dual-targeting strategy (MCM + KTP) and pH-responsive release together address key limitations of prior approaches, including poor specificity and off-target toxicity. While the study is preclinical, the use of biocompatible, naturally derived components and a scalable synthesis approach strengthens its translational case.